Signs, symptoms, and clinical forms of cataract in adults
Individuals with a personal or family history of medullary thyroid carcinoma (MTC) Those diagnosed with Multiple Endocrine Neoplasia syndrome type 2 (MEN2) Pregnant or breastfeeding individuals Patients with gastric emptying disorders (e.g., gastroparesis) Anyone with a known allergy to GLP-1 medications Individuals currently experiencing pancreatitis or at high risk for it Anyone whose medical history or medications contraindicate GLP-1 therapy (evaluated during consultation) Possible Side Effects Nausea, especially during initial dose increases Vomiting or mild gastrointestinal discomfort Constipation or diarrhea Decreased appetite Fatigue or low energy Bloating or gas Injection-site irritation Rare but serious risks such as pancreatitis or gallbladder issues Why Choose Juventas Wellness for GLP 1 Therapy in Denver
Whilst uncomfortable, these digestive symptoms are generally not dangerous and often improve with time and management strategies
STUB1 is upregulated in CD4+ T cells of SLE patients and promotes the expression of CD70 and CD11a, making it a potential therapeutic target
Hammer et al., 2008), potentially by acting on renal D1 receptors to mediate renal vasodilation and natriuresis (Armando et al., 2011)
